Franklin Resources Inc. Has $109.94 Million Holdings in Tempus AI, Inc. $TEM

Franklin Resources Inc. boosted its holdings in shares of Tempus AI, Inc. (NASDAQ:TEM) by 27.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,861,782 shares of the company’s stock after buying an additional 405,662 shares during the quarter. Franklin Resources Inc.’s holdings in Tempus AI were worth $109,938,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Los Angeles Capital Management LLC acquired a new position in Tempus AI during the fourth quarter worth approximately $27,000. J.W. Cole Advisors Inc. increased its position in Tempus AI by 14.8% during the fourth quarter. J.W. Cole Advisors Inc. now owns 16,135 shares of the company’s stock worth $953,000 after buying an additional 2,081 shares during the last quarter. CIBC Asset Management Inc increased its position in Tempus AI by 14.5% during the fourth quarter. CIBC Asset Management Inc now owns 5,401 shares of the company’s stock worth $319,000 after buying an additional 685 shares during the last quarter. AXQ Capital LP acquired a new position in Tempus AI during the fourth quarter worth approximately $1,535,000. Finally, Lingotto Investment Management LLP grew its position in shares of Tempus AI by 45.9% in the fourth quarter. Lingotto Investment Management LLP now owns 1,143,526 shares of the company’s stock valued at $67,525,000 after purchasing an additional 359,667 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Trading Up 1.4%

Shares of TEM stock opened at $49.48 on Thursday. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96. The stock has a market cap of $8.89 billion, a P/E ratio of -28.77 and a beta of 3.62. The stock has a 50 day simple moving average of $49.22 and a 200 day simple moving average of $57.03. Tempus AI, Inc. has a 1 year low of $41.73 and a 1 year high of $104.32.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.08. The business had revenue of $348.12 million during the quarter, compared to analysts’ expectations of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The firm’s revenue for the quarter was up 36.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.24) earnings per share. On average, research analysts predict that Tempus AI, Inc. will post -1.35 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 target price on shares of Tempus AI in a research report on Monday, June 1st. Wall Street Zen raised Tempus AI from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Wolfe Research assumed coverage on Tempus AI in a research report on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. Jefferies Financial Group assumed coverage on Tempus AI in a research report on Monday, April 13th. They issued an “underperform” rating and a $35.00 target price on the stock. Finally, Robert W. Baird assumed coverage on Tempus AI in a research report on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 target price on the stock. Nine research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $68.64.

More Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Several new write-ups highlighted Tempus AI as an attractive AI/healthcare name, citing its data moat, strong revenue growth, and improving margin profile, which could support investor confidence in the stock. Tempus AI: A Unique AI Business Model With Asymmetric Upside
• Positive Sentiment: Another analyst-focused article called TEM one of the best healthcare mid-cap AI stocks, reinforcing the idea that Wall Street sees upside in Tempus AI’s growth story. Tempus AI (TEM) Is One Of The Best Healthcare Mid-Cap AI Stock According To Analysts
• Positive Sentiment: Ambry Genetics, a Tempus subsidiary, announced peer-reviewed research showing its RNA testing may improve diagnostic clarity in exome testing, which supports Tempus’ diagnostics credibility and long-term platform value. Genetics in Medicine Open Study Demonstrates How Ambry Genetics’ ExomeReveal RNA Testing Can Improve Diagnostic Clarity in Exome Testing
• Neutral Sentiment: Tempus said it will report first-quarter 2025 results on May 6, a routine calendar item that keeps investors focused on upcoming earnings and guidance. Tempus to Report First Quarter 2025 Financial Results on May 6
• Neutral Sentiment: Brokerage summaries indicated TEM currently carries a consensus “Hold” rating, suggesting analysts remain constructive but not uniformly bullish. Tempus AI, Inc. Given Consensus Recommendation of Hold by Analysts
• Neutral Sentiment: Short-interest data appears incomplete and shows no meaningful short position, so it does not provide a clear trading signal right now.

Insiders Place Their Bets

In related news, CAO Ryan M. Bartolucci sold 4,116 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total value of $181,392.12. Following the completion of the sale, the chief accounting officer directly owned 74,041 shares in the company, valued at approximately $3,262,986.87. The trade was a 5.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Andrew Polovin sold 8,703 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total value of $383,541.21. Following the completion of the sale, the executive vice president owned 128,215 shares of the company’s stock, valued at approximately $5,650,435.05. This trade represents a 6.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 558,557 shares of company stock valued at $26,611,939 in the last quarter. Company insiders own 24.26% of the company’s stock.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.